||How Glaxo Wellcome developed an AIDS drug for children
New FDA regulations and innovative clinical trials enabled
Glaxo Wellcome to get much earlier approval to give
Abacavir to HIV-infected children.
||Waiting for cancer vaccines
Through decades of ups and downs, tumor immunologists have
spread the gospel that cancer vaccines are going to work.
Have cloned tumor antigens and dendritic cells finally
given them the tools to prove it?
||Designing taxanes to treat multidrug-resistant tumors
Iwao Ojima, Pierre-Yves Bounaud, and Ralph J. Bernacki
Taxanes are used as chemotherapeutics for certain types of
cancer because they inhibit cell mitosis. The basic structure of these
drugs can be altered to fight cancer by an entirely
different mechanism: inhibition of Pgp, a pump protein
responsible for multidrug resistance in tumors.
||Will super asprin supersede asprin?
The new COX-2 inhibitors target pain without the GI side
effects associated with long-term aspirin use. The market
for these drugs, which includes patients who suffer from
osteoarthritis, rheumatoid arthritis, and other types of
chronic pain, could be enormous.
||Bright ideas for high-throughput screening
One-step fluorescence HTS assays are getting faster,
cheaper, smaller, and more sensitive.